Equities

Vivos Inc

RDGL:QBB

Vivos Inc

Actions
Basic MaterialsChemicals
  • Price (USD)0.188
  • Today's Change0.009 / 4.79%
  • Shares traded1.18m
  • 1 Year change+230.62%
  • Beta0.9992
Data delayed at least 15 minutes, as of Jun 14 2024 20:58 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vivos Inc. is a radiation oncology medical device company. The Company is engaged in the development of its yttrium-90 (Y-90) based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. RadioGel is a device for human therapy for non-resectable cancers in humans. It is a hydrogel liquid containing tiny Yttrium-90 phosphate microparticles that may be administered directly into a tumor. The Company’s IsoPet division is focused on bringing RadioGel yttrium-90 precision radionuclide therapy to veterinary oncologists to treat dogs, cats and horses suffering from cancerous tumors. The IsoPet solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The Company is also engaged in developing a micro-injection system for small tumor therapy for treating cancerous thyroid lymph nodes.

  • Revenue in USD (TTM)18.00k
  • Net income in USD-3.20m
  • Incorporated2000
  • Employees10.00
  • Location
    Vivos Inc719 Jadwin AveRICHLAND 99352-4217United StatesUSA
  • Phone+1 (509) 736-4000
  • Fax+1 (509) 736-4007
  • Websitehttps://www.radiogel.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Beyond Air Inc689.00k-66.70m57.37m98.00--2.13--83.27-2.13-2.130.02190.58670.0111.441.247,030.61-112.64-70.88-148.49-88.69-115.24---10,288.68-1,530.313.26--0.382-------29.27------
Medinotec Inc3.05m-566.90k58.67m29.00--28.27--19.24-0.0483-0.04830.25980.17690.67122.0616.96105,130.70-12.48---13.23--53.56---18.59--8.571.440.4323---3.91---184.47------
Nutriband Inc2.02m-6.37m59.15m13.00--4.40--29.33-0.7639-0.76390.24341.220.16936.9316.15---53.45-55.21-58.89-66.7439.8933.32-315.74-315.876.04-81.810.0362--0.274153.43-22.35--65.57--
Heartbeam Inc0.00-15.11m60.56m15.00--4.83-----0.6111-0.61110.000.47620.00----0.00-200.17---258.74--------------0.00-------12.94------
Neuronetics Inc73.23m-27.54m60.60m202.00--2.19--0.8275-0.9484-0.94842.520.92260.70612.265.43360,714.30-26.56-28.02-30.98-34.7375.5275.73-37.61-51.045.18-4.270.6825--9.426.2218.76--18.57--
Hyperfine Inc11.69m-41.93m63.09m131.00--0.8342--5.40-0.5858-0.58580.16331.050.11271.032.8089,251.91-40.40---43.95--42.39---358.59--8.26--0.00--61.90--39.54------
InspireMD Inc6.48m-22.69m63.32m65.00--1.69--9.78-0.7594-0.75940.21081.500.20912.344.9799,646.16-73.26-60.59-86.14-72.9726.6520.46-350.35-334.787.41--0.00--20.0011.50-7.71--41.57--
Monogram Technologies Inc365.00k-13.39m65.24m28.00--6.37--178.74-0.4414-0.44140.0120.32330.0316----13,035.71-115.81-119.26-226.52-257.400.00---3,669.37-5,045.60----0.00-------0.3964---15.97--
Pro-Dex Inc49.46m4.35m66.06m146.0015.912.1612.091.341.211.2113.878.961.012.434.23338,753.408.9115.4311.2918.8727.9433.158.7914.922.0811.980.27510.009.6215.4654.7232.380.8422--
Vivos Inc18.00k-3.20m75.39m10.00--56.19--4,188.35-0.0087-0.00870.000050.00340.0127--3.13---225.38-202.25-235.64-552.77-33.3310.79-17,805.45-11,969.07----0.00---46.58---17.19------
T2 Biosystems Inc7.18m-45.65m78.52m113.00------10.94-17.91-17.912.21-6.850.24973.244.9363,504.43-158.80-106.01---253.03-116.97-12.60-636.09-317.930.1936--10.70---67.75-7.2919.66---20.19--
Sensus Healthcare Inc31.66m4.65m86.88m35.0018.591.7017.642.740.28510.28511.943.120.57211.021.96904,428.608.4110.299.4012.1460.3462.8514.7015.296.49--0.00---45.20-1.58-98.00---23.16--
Vivani Medical Inc0.00-25.37m87.97m44.00--3.06-----0.4954-0.49540.000.52220.00----0.00-51.59-56.58-58.76-67.66-------2,868.72----0.00-------84.69--40.33--
Vuzix Corp9.94m-49.96m89.32m94.00--1.22--8.98-0.7826-0.78260.15581.130.09971.302.52105,762.30-50.09-41.61-54.56-44.80-35.85-6.13-502.49-317.286.57--0.00--2.488.42-23.02--39.42--
Asensus Surgical Inc8.72m-78.71m89.87m207.00--6.89--10.30-0.3065-0.30650.03390.04790.12711.7913.0942,144.93-114.63-71.10-146.89-79.04-52.04-71.39-902.25-1,207.710.689--0.00--21.02-18.67-3.80---6.14--
Data as of Jun 14 2024. Currency figures normalised to Vivos Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.